(Reuters) - Staff reviewers from the U.S. Food and Drug Administration on Friday questioned if Clovis Oncology Inc's lung cancer drug was more effective than available treatments.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire